27-Apr-2020

Dr James Garner discusses paxalisib data with FNN

Our CEO, Dr James Garner recently conducted an interview with FNN which focused on the recent interim data from Kazia’s ongoing phase II trial of paxalisib in glioblastoma.

09-Apr-2020

Kazia CEO, Dr James Garner discusses the recent positive interim data from the phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising

Kazia CEO, Dr James Garner discusses the recent positive interim data from the ongoing phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising.